An Investigation of Extensively Drug - resistant Tuberculosis: Revealing Potential Improvements for Tuberculosis Control Program
DOI:
https://doi.org/10.59096/osir.v15i3.262368Keywords:
extensively drug-resistant tuberculosis, XDR-TB, health insurance, drug qualityAbstract
On 31 May 2019, the Division of Epidemiology (DoE) was notified of a confirmed extensively drug-resistant tuberculosis (XDR-TB) case in Bangkok. The DoE and local teams conducted a joint investigation to describe the epidemiological characteristics of the case, identify possible source cases and contacts, and implement control measures. A descriptive study was performed among cases and close contacts by interviewing and reviewing the medical records using a standard case definition. An environmental study was performed at the case's house, workplaces, and tuberculosis (TB) clinic. The TB drugs were tested to analyze the content of active ingredients and dissolution. The case was a 36-year-old Thai male. In 2011, he was diagnosed with pulmonary tuberculosis and had received inappropriate treatment. He developed multidrug-resistant tuberculosis (MDR-TB) eight months later and XDR-TB in May 2019 with delayed hospital admission. Two possible source cases, both co-workers of the index case, were identified. Of 21 contacts, 13 were screened with a chest x-ray and found to have no abnormality. At the TB-clinic, drugs were stored in a room with inappropriate levels of temperature and humidity; however, the content of active ingredients and dissolution of TB drugs were within normal limits. Early hospital admission and monitoring of drug stockpile environments according to standard guidelines are recommended.
References
World Health Organization. Tuberculosis (TB) [Internet]. World Health Organization; [cited 2019 Nov 8]. <https://www.who.int/news-room/fact-sheets/detail/tuberculosis>
Shah NS, Wright A, Bai GH, Barrera L, Boulahbal F, Martin-Casabona N, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis. 2007;13(3):380–7.
Migliori GB, Loddenkemper R, Blasi F, Raviglione MC. 125 years after Robert Koch’s discovery of the tubercle bacillus: The new XDR-TB threat. Is “science” enough to tackle the epidemic? Eur Respir J. 2007;29(3):423–7.
Zignol M, Hosseini MS, Wright A, Weezenbeek CL, Nunn P, Watt CJ, et al. Global incidence of multidrug-resistant tuberculosis. J Infect Dis. 2006 Aug 15;194(4):479–85.
Matteelli A, Migliori GB, Cirillo DM, Centis R, Girardi E, Raviglione MC. Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: epidemiology and control. Expert Rev Anti Infect Ther. 2007 Oct;5(5):857–71.
World Health Organization. Drug-resistant TB: XDR-TB FAQ [Internet]. Geneva: World Health Organization; 2018 [cited 2019 Nov 8]. <https://www.who.int/tb/areas-of-work/drug-resistant-tb/XDR-TB-faq/en/>
World Health Organization. TB drug resistance types [Internet]. Geneva: World Health Organization; 2015 [cited 2019 Nov 8]. <https://www.who.int/tb/areas-of-work/drug-resistant-tb/types/en/>
World Health Organization. Global tuberculosis report 2018. Geneva: World Health Organization; 2018. 231 p.
Jiraphongsa C, Wangteeraprasert T, Henpraserttae N, Sanguanwongse N, Panya L, Sukkasitvanichkul J, et al. Community outbreak of multiple drug resistance tuberculosis, Kanchanaburi province, Thailand on 2002–June 2010. Journal of Preventive Medicine Association of Thailand. 2011 Sep–Dec;1(3):261–71. Thai.
Oeltmann JE, Varma JK, Ortega L, Liu Y, O’Rourke T, Cano M, et al. Multidrug-resistant tuberculosis outbreak among US-bound Hmong refugees, Thailand, 2005. Emerg Infect Dis. 2008 Nov;14(11):1715–21.
Communicable disease act B.E. 2558 (2015), Royal Thai Government Gazette [English version on the Internet], Volume 132, part 86 Kor (Dated 2015 Sep 8) [cited 2019 Nov 8]:26–44. <https://ddc.moph.go.th/uploads/ckeditor/c74d97b01eae257e44aa9d5bade97baf/files/001_2gcd.pdf>
National Tuberculosis control programme guidelines, Thailand, 2018. Bangkok: Division of Tuberculosis, Department of Disease Control; 2018. 120 p.
Tuberculosis investigation and control guidelines, Thailand, 2018. Bangkok: Division of Tuberculosis, Department of Disease Control; 2018. 80 p.
World Health Organization. A patient-centred approach to TB care [Internet]. Geneva: World Health Organization; 2018 [cited 2019 Nov 17]. 2 p. <https://apps.who.int/iris/bitstream/handle/10665/272467/WHO-CDS-TB-2018.13-eng.pdf?ua=1>
Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention. A new tool to diagnose tuberculosis: the Xpert MTB/RIF assay [Internet]. Atlanta: Centers for Disease Control and Prevention; [cited 2020 Apr 11]. 2 p. <https://www.cdc.gov/tb/publications/factsheets/pdf/xpertmtb-rifassayfactsheet_final.pdf>
Pharmapproch. Quality control tests for tablets [Internet]. [place unknown]: Pharmapproach.com; 2019 [cited 2019 Oct 23]. <https://www.pharmapproach.com/quality-control-tests-for-tablets/>
Sumriddetchkajorn K, Shimazaki K, Ono T, Kusaba T, Sato K, Kobayashi N. Universal health coverage and primary care, Thailand. Bull World Health Organ. 2019 Jun 1;97(6):415–22.
Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention. Tuberculosis: Drug-resistant TB [Internet]. Atlanta: Centers for Disease Control and Prevention; 2017 [cited 2018 Jun 10]. <https://www.cdc.gov/tb/topic/drtb/default.htm>
Cox H, Kebede Y, Allamuratova S, Ismailov G, Davletmuratova Z, Byrnes G, et al. Tuberculosis recurrence and mortality after successful treatment: Impact of drug resistance. PLoS Med. 2006 Oct;3(10):e384. doi:10.1371/journal.pmed.0030384.
Bestrashniy JRBM, Nguyen VN, Nguyen TL, Pham TL, Nguyen TA, Pham DC, et al. Recurrence of tuberculosis among patients following treatment completion in eight provinces of Vietnam: A nested case-control study. Int J Infect Dis. 2018 Sep [cited 2020 Apr 11];74:31–7. <https://www.sciencedirect.com/science/article/pii/S1201971218344485>
Dooley KE, Lahlou O, Ghali I, Knudsen J, Elmessaoudi MD, Cherkaout I, et al. Risk factors for tuberculosis treatment failure, default, or relapse and outcomes of retreatment in Morocco. BMC Pulic Health. 2011 Feb 28;11:140.
Raviglione MC, Smith IM. XDR tuberculosis— implications for global public health. N Engl J Med. 2007 Feb 15;356(7):656–9.
Ebrahim GJ. Drug resistance in tuberculosis. J Trop Pediatr. 2007 Jun;53(3):147–9.
Division of Tuberculosis. Tuberculosis Case Management [Internet]. Bangkok: Division of Tuberculosis, Department of Disease Control; [cited 2019 Dec 15]. <https://tbcmthailand.ddc.moph.go.th/uiform/>
Santos E, Felgueiras O, Oliveira O, Duarte R. Factors associated with loss to follow-up in Tuberculosis treatment in the Huambo Province, Angola. Pulmonology. 2019 May–Jun;25(3);190–2.
Abubakar I, Lipman M. Reducing loss to follow-up during treatment for drug-resistant tuberculosis Ibrahim. Eur Respir J. 2019 Jan 10;53(1):1802268.
McMullen CK, Safford MM, Bosworth HB, Phansalkar S, Leong A, Fagan MB, et al. Patient-centered priorities for improving medication management and adherence. Patient Educ Couns. 2015 Jan;98(1):102–10.
Gargioni, G. Role of communities in tuberculosis care and Prevention [Internet]. [place unknown]: Z-Library; 2009 [cited 2019 Nov 19]. p. 660–7. doi:10.1016/b978-1-4160-3988-4.00064-0.
Araujo-Filho JA, Vasconcelos AC Jr, Sousa EM, Silveira Cd, Ribeiro E, Kipnis A, et al. Extensively drug-resistant tuberculosis: a case report and literature review. Braz J Infect Dis. 2008;12(5):447–52. doi:10.1590/s1413-86702008000500019.
World Health Organization. Implementing tuberculosis diagnostics: a policy framework [Internet]. Geneva: World Health Organization; 2015 [cited 2020 Jan 3]. <https://apps.who.int/iris/handle/10665/162712>
Reechaipichitkul W, Netniyom S, Pungrassami P, editors. Guideline for programmatic management of drug-resistant tuberculosis. Bangkok (TH): Division of Tuberculosis, Department of Disease Control; 2015 May. 97 p. Thai.
Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR Recomm Rep. 1998 Oct 30;47(RR-20):1–58.
Lawn SD, Wilkinson R. Extensively drug resistant tuberculosis. BMJ. 2006 Sep 16;333(7568):559–60.
Cao K, Yang K, Wang C, Guo J, Tao L, Liu Q, et al. Spatial-temporal epidemiology of tuberculosis in Mainland China: An analysis based on bayesian theory. Int J Environ Res Public Health. 2016 May 5;13(5):469.
Onozuka D, Hagihara A. The association of extreme temperatures and the incidence of tuberculosis in Japan. Int J Biometeorol. 2015 Aug;59(8):1107–14.
Rao HX, Zhang X, Zhao L, Yu J, Ren W, Zhang XL, et al. Spatial transmission and meteorological determinants of tuberculosis incidence in Qinghai province, China: A spatial clustering panel analysis. Infect Dis Poverty. 2016 Jun 2;5(1):45.
Yanagawa H, Hara N, Hashimoto T, Yokoyama H, Tachibana K. Geographical pattern of tuberculosis and related factors in Japan. Soc Sci Med Med Geogr. 1981 Feb;15(1):141–8.
World Health Organization. Survey of the quality of anti-tuberculosis medicines circulating in selected newly independent states of the former Soviet Union [Internet]. Geneva: World Health Organization; 2012 Feb 4 [cited 2019 Nov 11]. <https://www.who.int/news/item/04-02-2012-survey-of-the-quality-of-anti-tuberculosis-medicines-circulating-in-selected-newly-independent-states-of-the-former-soviet-union>
Burugina Nagaraja S, Satyanarayana S, Chadha SS, Kalemane S, Jaju J, Achanta S, et al. How do patients who fail first-line TB treatment but who are not placed on an MDR-TB regimen fare in South India? PLoS ONE. 2011 Oct 11;6(10):e25698. doi:10.1371/journal.pone.0025698.
Reid MJA, Goosby E. Patient-centered tuberculosis programs are necessary to end the epidemic. J Infect Dis. 2017 Nov 6;216(Suppl 7):S673–4.
Ministerial regulations: the criteria and procedure for medical examination of employees, and submission of examination result to Labor Official, B.E. 2547 (2004), Royal Thai Government Gazette Volume 122, part 4 Kor (Dated 2005 Jan 13):19–22. <http://www3.mol.go.th/sites/default/files/laws/th/00151640.pdf>
World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization; 2014. 403 p.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Outbreak, Surveillance, Investigation & Response (OSIR) Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
